BioCentury | Jan 20, 2021

IPO queue upswelling: Data Byte

With two biopharmas already trading on NASDAQ following their IPOs this month, the queue of companies seeking public listings has begun to swell. Seven therapeutics developers filed for offerings late Friday, ready to test investors’...
BioCentury | Jan 15, 2021

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

A broad syndicate has funded NewAmsterdam with a $196 million (€160 million) series A round to assess whether a well-traveled CETP inhibitor can find a place in the treatment paradigm for dyslipidemia. Forbion, Morningside Ventures...
BioCentury | Jan 13, 2021
Management Tracks

Spark vet High joins AskBio; plus Rotthier to lead Sanofi API unit and moves at Immunovant, Innocoll

The Asklepios BioPharmaceutical Inc. (AskBio) unit of Bayer AG (Xetra:BAYN) hired Spark Therapeutics Inc. alum Katherine High as president, therapeutics. As president and head of R&D at Spark, High led the development and regulatory approval of Luxturna...
BioCentury | Jan 8, 2021

More strategics pile into Dutch early-stage investor BGV’s largest-ever fund

BioGeneration Ventures has topped off its largest-ever fund with a further €35 million and new strategic backers Lilly and Novo Ventures.  The €140 million ($172 million) BGV IV brings the Dutch VC’s assets under management to €250...
BioCentury | Dec 17, 2020

Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero

First approval for MacroGenics FDA approved Margenza margetuximab-cmkb from MacroGenics Inc. (NASDAQ:MGNX) — the company’s first approved drug — to treat metastatic HER2-positive breast cancer patients...
BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

NIH panel says bamlanivimab should not be considered standard-of-care for COVID-19NIH’s COVID-19 Treatment Guidelines Panel said there is not enough data to recommend either for or against use of bamlanivimab from Eli Lilly and Co. (NYSE:LLY)...
BioCentury | Nov 17, 2020

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

Roche, Lead Pharma form immunology partnershipDutch biotech Lead Pharma Holding B.V. will collaborate with Roche (SIX:ROG; OTCQX:RHHBY) to develop preclinical small molecules against a single, undisclosed target to treat immune-mediated diseases. Lead will receive €10 million...
BioCentury | Nov 13, 2020

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

A Cherry in MorphoSys’ hunt for new techMorphoSys AG (Xetra:MOR; NASDAQ:MOR) entered an exclusive licensing agreement with University Hospital Würzburg spinout Cherry Biolabs GmbH for access to its Hemibody platform to discover and develop T...
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

Gene therapy developer Freeline Therapeutics Holdings plc (NASDAQ:FRLN) hired Mark Baldry as chief commercial officer. He previously held the same role at Wave Life Sciences Ltd. (NASDAQ:WVE).  Rare disease play X4 Pharmaceuticals Inc. (NASDAQ:XFOR) appointed...
BioCentury | Oct 7, 2020

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

Roche’s deal to acquire a clinical cystic fibrosis program from U.K.-based Enterprise delivers a return to the biotech’s shareholders while allowing the venture-backed company to continue development of another pipeline project. Roche (SIX:ROG; OTCQX:RHHBY) is...
Items per page:
1 - 10 of 1700